Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the global burden of disease study 2019. Lancet Respir Med. 2021;9(9):1030–1049.
   Web of Science ®Google Scholar
• Dela CC, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–644.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer. Int J Mol Sci. 2021;22(5):2625.
   PubMed Web of Science ®Google Scholar
• Zito MF, Ali G, Facchinetti F, et al. Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy. Expert Rev Anticancer Ther. 2021;21(8):887–900.
   PubMed Web of Science ®Google Scholar
• Kim S, Oh IJ, Park SY, et al. Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer. J Thorac Dis. 2014;6(9):1209–1217.
   PubMed Web of Science ®Google Scholar
• Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356.
   PubMed Web of Science ®Google Scholar
• Gemma A, Kusumoto M, Kurihara Y, et al. Interstitial lung disease onset and its risk factors in Japanese patients with ALK-Positive NSCLC after treatment with crizotinib. J Thorac Oncol. 2019;14(4):672–682.
   PubMed Web of Science ®Google Scholar
• Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24(16):2549–2556.
   PubMed Web of Science ®Google Scholar
• Chung C. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. J Oncol Pharm Pract. 2016;22(3):461–476.
   PubMed Web of Science ®Google Scholar
• Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008;10(3):242–248.
   PubMed Web of Science ®Google Scholar
• Yatabe Y, Kerr KM, Utomo A, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015;10(3):438–445.
   PubMed Web of Science ®Google Scholar
• Tan DS, Yom SS, Tsao MS, et al. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol. 2016;11(7):946–963.
   PubMed Web of Science ®Google Scholar
• Le T, Gerber DE. Newer-Generation EGFR inhibitors in lung cancer: how are they best used? Cancers (Basel). 2019;11(3):366.
   PubMed Web of Science ®Google Scholar
• Bui KT, Cooper WA, Kao S, et al. Targeted molecular treatments in non-small cell lung cancer: a clinical guide for oncologists. J Clin Med. 2018;7(8):192.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–1889.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Sakata Y, Sakata S, Oya Y, et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021;159:144–153.
   PubMed Web of Science ®Google Scholar
• Qi WX, Sun YJ, Shen Z, et al. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. J Chemother. 2015;27(1):40–51.
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yamaoka T, Ando K, et al. Molecular and clinical features of EGFR-TKI-Associated lung injury. Int J Mol Sci. 2021;22(2):792.
   Web of Science ®Google Scholar
• Akamatsu H, Katakami N, Okamoto I, et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci. 2018;109(6):1930–1938.
   PubMed Web of Science ®Google Scholar
• Ohe Y, Imamura F, Nogami N, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol. 2019;49(1):29–36.
   PubMed Web of Science ®Google Scholar
• Shah RR. Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas. Drug Saf. 2016;39(11):1073–1091.
   PubMed Web of Science ®Google Scholar
• Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 2019;42(2):181–198.
   PubMed Web of Science ®Google Scholar
• Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci. 2014;105(12):1584–1590.
   PubMed Web of Science ®Google Scholar
• Ding PN, Lord SJ, Gebski V, et al. Risk of Treatment-Related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(4):633–643.
   PubMed Web of Science ®Google Scholar
• Uchida T, Kaira K, Yamaguchi O, et al. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. Thorac Cancer. 2019;10(4):975–979.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507–516.
   PubMed Web of Science ®Google Scholar
• Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in Nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112–1115.
   PubMed Web of Science ®Google Scholar
• Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–635.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–1669.
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-Mutated lung cancer. J Clin Oncol. 2020;38(2):124–136.
   PubMed Web of Science ®Google Scholar
• Suh CH, Kim KW, Nishino M. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer. 2019;127:168–169.
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama lung cancer study group. Cancer J. 2005;11(5):417–424.
   PubMed Web of Science ®Google Scholar
• Wrona A, Dziadziuszko R, Jassem J. Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents. Transl Lung Cancer Res. 2021;10(4):2032–2047.
   PubMed Web of Science ®Google Scholar
• Kong FM, Ten HR, Eisbruch A, et al. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol. 2005;32(2 Suppl 3):S42–S54.
   PubMed Web of Science ®Google Scholar
• Fu Z, Yang X, Wang W, et al. Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial. Radiat Oncol. 2020;15(1):155.
   PubMed Web of Science ®Google Scholar
• Xu K, Liang J, Zhang T, et al. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. Thorac Cancer. 2021;12(6):814–823.
   PubMed Web of Science ®Google Scholar
• Zheng L, Wang Y, Xu Z, et al. Concurrent EGFR-TKI and thoracic radiotherapy as First-Line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24(8):1031–1612.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Yuan Z, Chang JY, et al. Radiation pneumonitis in patients with non-small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol. 2014;9(6):882–885.
   PubMed Web of Science ®Google Scholar
• Jia W, Gao Q, Wang M, et al. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. Radiat Oncol. 2021;16(1):41.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JN, Bloom R, Forys JT, et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Mod Pathol. 2018;31(5):791–808.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273–4281.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Sgambato A, Casaluce F, Maione P, et al. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 2018;18(1):71–80.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang W. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in nonsmall cell lung cancer (review). Oncol Rep. 2021;45(1):13–28.
   PubMed Web of Science ®Google Scholar
• Yoneda KY, Scranton JR, Cadogan MA, et al. Interstitial lung disease associated with crizotinib in patients with advanced non-small cell lung cancer: independent review of four PROFILE trials. Clin Lung Cancer. 2017;18(5):472–479.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–2039.
   PubMed Web of Science ®Google Scholar
• Ando K, Manabe R, Kishino Y, et al. Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis. Cancers (Basel). 2021;13(15):3704.
   PubMed Web of Science ®Google Scholar
• Patel SP, Pakkala S, Pennell NA, et al. Phase Ib study of crizotinib plus pembrolizumab in patients with previously untreated advanced non-small cell lung cancer with ALK translocation. Oncologist. 2020;25(7):562–1012.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Reynolds C, Waterhouse D, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (checkmate 370). J Thorac Oncol. 2018;13(5):682–688.
   PubMed Web of Science ®Google Scholar
• Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013;19(15):4040–4045.
   PubMed Web of Science ®Google Scholar
• Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24(9):2364–2370.
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870.
   PubMed Web of Science ®Google Scholar
• Chin LP, Soo RA, Soong R, et al. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7(11):1625–1630.
   PubMed Web of Science ®Google Scholar
• Remon J, Pignataro D, Novello S, et al. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. Cancer Treat Rev. 2021;95:102178.
   PubMed Web of Science ®Google Scholar
• Azelby CM, Sakamoto MR, Bowles DW. ROS1 targeted therapies: current status. Curr Oncol Rep. 2021;23(8):94.
   PubMed Web of Science ®Google Scholar
• Wu YL, Yang JC, Kim DW, et al. Phase II study of crizotinib in east Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(14):1405–1411.
   PubMed Web of Science ®Google Scholar
• Liu C, Yu H, Chang J, et al. Crizotinib in Chinese patients with ROS1-rearranged advanced non‒small-cell lung cancer in routine clinical practice. Target Oncol. 2019;14(3):315–323.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):261–270.
   PubMed Web of Science ®Google Scholar
• Sun TY, Niu X, Chakraborty A, et al. Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer. J Thorac Oncol. 2019;14(2):e21–e24.
   PubMed Web of Science ®Google Scholar
• Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613–2618.
   PubMed Web of Science ®Google Scholar
• Shi L, Tang J, Tong L, et al. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and Meta-analysis of clinical trials. Lung Cancer. 2014;83(2):231–239.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Elhalawani H. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative Meta-analysis. Future Oncol. 2015;11(7):1109–1122.
   PubMed Web of Science ®Google Scholar
• Hong D, Zhang G, Zhang X, et al. Pulmonary toxicities of gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(9):e3008.
   PubMed Web of Science ®Google Scholar
• Suh CH, Kim KW, Pyo J, et al. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and Meta-analysis. Lung Cancer. 2019;132:79–86.
   PubMed Web of Science ®Google Scholar
• Li AY, Mccusker MG, Russo A, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019;81:101911.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014;84(2):121–126.
   PubMed Web of Science ®Google Scholar
• Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-Centre, phase 2, single-arm trial. Lancet Oncol. 2016;17(12):1653–1660.
   PubMed Web of Science ®Google Scholar
• Kodama T, Tsukaguchi T, Satoh Y, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014;13(12):2910–2918.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017;28(2):292–297.
   PubMed Web of Science ®Google Scholar
• Markham A. Selpercatinib: first approval. Drugs. 2020;80(11):1119–1124.
   PubMed Web of Science ®Google Scholar
• Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(8):1059–1066.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda T, Yanagi T. Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma. Biochem Biophys Res Commun. 2020;531(3):396–401.
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147–153.
   PubMed Web of Science ®Google Scholar
• Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of Non-Small-Cell lung cancer harboring an NTRK gene fusion. J Clin Oncol Precis Oncol. 2018;2018(2):1–12.
   Google Scholar
• Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.
   PubMed Web of Science ®Google Scholar
• Hong DS, Dubois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–540.
   PubMed Web of Science ®Google Scholar
• Aida S, Tamai S, Sekiguchi S, et al. Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies. Respiration. 1994;61(3):161–166.
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer. 2004;91(Suppl 2):S31–S37.
   Web of Science ®Google Scholar
• He Y, Zhou C. Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management. Transl Lung Cancer Res. 2019;8(Suppl 3):S318–S320.
   PubMed Web of Science ®Google Scholar
• Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget. 2013;4(4):550–559.
   PubMedGoogle Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27.
   PubMed Web of Science ®Google Scholar
• Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol. 2010;298(6):L715–L731.
   PubMed Web of Science ®Google Scholar
• Venkataraman T, Coleman CM, Frieman MB. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection. J Virol. 2017;91(12):e00182-17.
   Web of Science ®Google Scholar
• Yamaoka T, Arata S, Homma M, et al. Blockade of EGFR activation promotes TNF-Induced lung epithelial cell apoptosis and pulmonary injury. Int J Mol Sci. 2019;20(16):4021.
   PubMed Web of Science ®Google Scholar
• Gong K, Guo G, Gerber DE, et al. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest. 2018;128(6):2500–2518.
   PubMed Web of Science ®Google Scholar
• Shim JJ, Dabbagh K, Ueki IF, et al. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L134–L140.
   PubMed Web of Science ®Google Scholar
• Cheng CY, Kuo CT, Lin CC, et al. IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. Br J Pharmacol. 2010;160(7):1595–1610.
   PubMed Web of Science ®Google Scholar
• Kuwahara I, Lillehoj EP, Lu W, et al. Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-{kappa}B activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol. 2006;291(3):L407–L416.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Aoshiba K, Yokohori N, et al. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 2003;63(16):5054–5059.
   PubMed Web of Science ®Google Scholar
• Min JH, Lee HY, Lim H, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol. 2011;68(5):1099–1109.
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hagimoto N, Maeyama T, et al. Mitochondria-mediated apoptosis of lung epithelial cells in idiopathic interstitial pneumonias. Lab Invest. 2002;82(12):1695–1706.
   PubMed Web of Science ®Google Scholar
• Li C, Wei R, Jones-Hall YL, et al. Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association study. Sci Rep. 2014;4:4893.
   PubMed Web of Science ®Google Scholar
• Chang HL, Chen YH, Taiwan HC, et al. EGFR tyrosine kinase inhibitor-associated interstitial lung disease during the coronavirus disease 2019 pandemic. J Thorac Oncol. 2020;15(8):e129–e131.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nakao S, Hasegawa S, et al. Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database. SAGE Open Med. 2020;8:2050312120918264.
   Web of Science ®Google Scholar
• Niho S, Goto K, Yoh K, et al. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Jpn J Clin Oncol. 2006;36(5):269–273.
   PubMed Web of Science ®Google Scholar
• Endo M, Johkoh T, Kimura K, et al. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the west Japan thoracic oncology group. Lung Cancer. 2006;52(2):135–140.
   PubMed Web of Science ®Google Scholar
• Koshikawa K, Terada J, Abe M, et al. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: a single center retrospective analysis. Thorac Cancer. 2020;11(6):1495–1502.
   PubMed Web of Science ®Google Scholar
• Meyer KC, Raghu G, Baughman RP, et al. An official American thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–1014.
   PubMed Web of Science ®Google Scholar
• Myall NJ, Lei AQ, Wakelee HA. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series. Transl Lung Cancer Res. 2021;10(1):487–495.
   PubMed Web of Science ®Google Scholar
• Harrison PK, Boland HE, Aherne NJ, et al. An unusual case of lorlatinib-induced pneumonitis: a case report. Case Rep Oncol. 2022;15(1):225–230.
   PubMed Web of Science ®Google Scholar
• Sato Y, Sekine A, Hagiwara E, et al. Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: a case report. Respir Med Case Rep. 2021;33:101450.
   PubMed Web of Science ®Google Scholar
• Sakata Y, Kawamura K, Shingu N, et al. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events. Asia Pac J Clin Oncol. 2020;16(2):e113–e117.
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Tsurutani J, et al. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Jpn J Clin Oncol. 2012;42(6):528–533.
   PubMed Web of Science ®Google Scholar
• Kuo LC, Lin PC, Wang KF, et al. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol. 2011;28(1):79–82.
   PubMed Web of Science ®Google Scholar
• Seto T, Seki N, Uematsu K, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology. 2006;11(1):113–116.
   PubMed Web of Science ®Google Scholar
• Kashiwabara K, Semba H, Fujii S, et al. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease. Cancer Chemother Pharmacol. 2017;79(4):705–710.
   PubMed Web of Science ®Google Scholar
• Kiriu T, Tamura D, Tachihara M, et al. Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease. Intern Med. 2018;57(1):91–95.
   PubMed Web of Science ®Google Scholar
• Bickert C, Kahnert K, Kauffmann-Guerrero D, et al. Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies. Ther Adv Med Oncol. 2021;13:17588359211018028.
   Google Scholar
• Pan Y, Xiao W, Ye F, et al. Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion. Ann Transl Med. 2021;9(12):1014.
   PubMed Web of Science ®Google Scholar
• Mackintosh JA, Marshall HM, Fong KM. A targeted approach to the complications of targeted therapy. J Thorac Oncol. 2019;14(4):577–579.
   PubMed Web of Science ®Google Scholar
• Mahmutovic PI, von Wachenfeldt K, Waterton JC, et al. Imaging biomarkers in animal models of drug-induced lung injury: a systematic review. J Clin Med. 2020;10(1):107.
   Web of Science ®Google Scholar
• Solassol I, Pinguet F, Quantin X. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management. Biomolecules. 2019;9(11):668.
   PubMed Web of Science ®Google Scholar
• Jung J, Kim HY, Kim DG, et al. Sequential treatment with an immune checkpoint inhibitor followed by a Small-Molecule targeted agent increases drug-induced pneumonitis. Cancer Res Treat. 2021;53(1):77–86.
   PubMed Web of Science ®Google Scholar
• Li L, Huang W, Li K, et al. Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget. 2015;6(41):43605–43619.
   PubMedGoogle Scholar